CDX-011, or Glembatumumab (Celldex), is an antibody targeted against GPNMB (Transmembrane Protein NMB); this antibody was conjugated to vedotin (monomethyl auristatin E), a highly potent antimitotic agent, in recent Phase 2 trials for advanced breast cancer and late-stage melanoma [60, 61]. Here, GPNMB is linked to breast cancer.